Atara Biotherapeutics Inc
NASDAQ:ATRA
Atara Biotherapeutics Inc
Capital Expenditures
Atara Biotherapeutics Inc
Capital Expenditures Peer Comparison
Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors
Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Atara Biotherapeutics Inc
NASDAQ:ATRA
|
Capital Expenditures
$-1.2m
|
CAGR 3-Years
43%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Capital Expenditures
$-777m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Capital Expenditures
$-585m
|
CAGR 3-Years
3%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-12%
|
|
Amgen Inc
NASDAQ:AMGN
|
Capital Expenditures
$-1.1B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-5%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Capital Expenditures
$-258.4m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-18%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Capital Expenditures
$-926.4m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-19%
|
See Also
What is Atara Biotherapeutics Inc's Capital Expenditures?
Capital Expenditures
-1.2m
USD
Based on the financial report for Sep 30, 2023, Atara Biotherapeutics Inc's Capital Expenditures amounts to -1.2m USD.
What is Atara Biotherapeutics Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
51%
Over the last year, the Capital Expenditures growth was 82%. The average annual Capital Expenditures growth rates for Atara Biotherapeutics Inc have been 43% over the past three years , 51% over the past five years .